Cutting-edge digital diagnostic tool eliminates need for traditional culture methods

Innominds, a US-based digital transformation and product engineering company, has announced its partnership with Hyderabad-based startup SCIINV Biosciences to introduce AMRx, an advanced AI/ML-driven digital diagnostic tool designed to combat the growing threat of antimicrobial resistance (AMR).

 

This innovative tool promises to revolutionise the detection and treatment of antibiotic-resistant infections without the need for traditional cultures.

 

AMRx, developed by Innominds and SCIINV Biosciences, is a groundbreaking, culture-free companion diagnostic tool that utilises AI/ML to predict Urinary Tract Infections (UTIs) and determine antibiotic resistance patterns based on patient clinical history. This patented technology represents a significant advancement in the fight against AMR.

 

AMRx leverages patient clinical history to accurately predict UTIs, identify causative organisms (Enterobacteriaceae), and determine antibiotic resistance or susceptibility patterns without the need for traditional cultures.

 

By reducing unwarranted clinical investigations, AMRx saves valuable time, effort, and resources. This efficiency is particularly beneficial in resource-limited settings.

 

AMRx can be deployed as a clinical decision support tool, aiding healthcare professionals in making appropriate empirical antibiotic prescriptions, thereby enhancing the accuracy and effectiveness of treatment.